drugset / Trial / NCT07080619
SC-101 in Subjects With Advanced NECTIN4-Amplified Cancers
NaSingle-groupOpen-labelTreatment
Summary
This study is an open-label, multicenter Phase IIa trial to evaluate the efficacy and safety of SC-101 monotherapy in patients with locally advanced or metastatic malignant tumors who are positive for NECTIN4 gene amplification.
Timeline
- Start
- 2025-09-20
- Primary completion
- 2027-07-30
- Completion
- 2027-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SC-101 | Small interfering RNA (siRNA) | 7.5 mg/m2 | Intravenous |